Reviewing EDIT-301 as an experimental cell therapy medicine for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)

Executed on:Mar 3, 2023 10:00 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Howard UniversityProfessor of Medicine and Microbiology/Immunology & Director or the Center for Sickle Cell Disease at Howard University (previously held positions at the NIH and Johns Hopkins).
Manages 355 patients with Sickle Cell Disease, 2 active Beta-Thalassemia patients and 1 HbH disease patient.
Research interests include the use of genetic tools to understand and treat sickle cell disease and complications of transfusion therapy.

Interview Goal

Discussing the potential of Editas Medicines' EDIT-301 and the recent results from the RUBY trial, a single-arm, open-label, multi-center Phase 1/2 study

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.